These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37247166)

  • 21. Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study.
    Cheng Y; Pan Z; Wu L; Zhu B; Yu Y; Zang K; Zhuang W; Liu L; Gu K; Lian J; Chen R; Bian T; Lin D; Sun S; Li W; Hang X; Jiang O; Zhong F; Wang R; Luo H; Shi H; Wei Z; Zhao L; Chen S; Sun H; Li X; Sun D; Ren T; Lei K; He M; Li G; Liu H; Li R; Hu C; Kong L; Sun M; Xie L; Gai W; Chen W; Huang Z; Ren W; Su H
    Adv Ther; 2024 Nov; 41(11):4032-4048. PubMed ID: 39230871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects.
    Cao G; Yu J; Wu J; Wang J; Xue Y; Yang X; Zhang J
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):317-325. PubMed ID: 32463599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers.
    Sinn A; García-Alvarado F; Gonzalez V; Huerga C; Bullo F
    Br J Clin Pharmacol; 2022 Mar; 88(3):1063-1073. PubMed ID: 34374114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects.
    Hanes V; Chow V; Pan Z; Markus R
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):899-905. PubMed ID: 30269275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects.
    Zhang Q; Sun C; Wu J; Wu J; Zhang X; Liu Y; Dou C; Qin H; Zhang Q; Zhou R; Hu W
    Expert Opin Biol Ther; 2023; 23(8):727-735. PubMed ID: 36880118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers.
    Wang J; Qi L; Liu L; Wang Z; Chen G; Wang Y; Liu X; Liu Y; Liu H; Tong Y; Liu C; Lei C; Wang X
    Front Pharmacol; 2019; 10():905. PubMed ID: 31474863
    [No Abstract]   [Full Text] [Related]  

  • 27. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers.
    Knight B; Rassam D; Liao S; Ewesuedo R
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):839-46. PubMed ID: 26984210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men.
    Markus R; Chow V; Pan Z; Hanes V
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):755-763. PubMed ID: 28864922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers.
    Eto T; Karasuyama Y; González V; Del Campo García A
    Cancer Chemother Pharmacol; 2021 Oct; 88(4):713-722. PubMed ID: 34269848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics, safety, tolerability, and immunogenicity of FKB238, a new biosimilar of bevacizumab, in healthy participants.
    Boyce M; Wilkes D; Kaito H; Takanuma M; Arai Y
    Int J Clin Pharmacol Ther; 2022 Jun; 60(6):280-290. PubMed ID: 35361328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Randomized, Double-Blind, Single-Dose Study Comparing the Biosimilarity of HOT-1010 With Bevacizumab (Avastin®) in Chinese Healthy Male Subjects.
    Huang K; Que L; Ding Y; Chu N; Qian Z; Shi Y; Qin W; Li Z; Chen Y; Gu X; Wang J; Zhang L; Zhang J; Zhu X; Yang Y; Tang Y; He Q
    Front Pharmacol; 2021; 12():694375. PubMed ID: 34220519
    [No Abstract]   [Full Text] [Related]  

  • 32. A Phase I Clinical Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of GB221 Injection and Trastuzumab (Herceptin
    Zhu Y; Li C; Chen L; Liu H; Ou L; Li T; Wang X; Wang T; Tian J; Liang X; Hu Z; Zhan Y; Xiao S; Wang X; Li Y; He J; Zheng Q; Song H; Li X; Fang Y
    Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):383-392. PubMed ID: 38564097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized trial comparing LY01011, biosimilar candidate, with the reference product denosumab (Xgeva®) in healthy Chinese subjects.
    Ding Y; Liu Y; Dou C; Guo S
    J Bone Oncol; 2023 Oct; 42():100499. PubMed ID: 37701913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects.
    Zhang H; Li Q; Zhu X; Li C; Li X; Liu C; Hu Y; Chen G; Wei H; Wang J; Shen Z; Ding Y
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):615-623. PubMed ID: 30043208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double-blind, parallel-controlled, phase 1 study.
    Zhang H; Wu M; Sun J; Zhu X; Li C; Ding Y; Zhang X; Chai K; Li X
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00733. PubMed ID: 33682358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects.
    Hettema W; Wynne C; Lang B; Altendorfer M; Czeloth N; Lohmann R; Athalye S; Schliephake D
    Expert Opin Investig Drugs; 2017 Aug; 26(8):889-896. PubMed ID: 28651442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women.
    Fenwick S; Vekariya V; Patel R; Hajela P; Modi K; Kale P; Nath A
    Osteoporos Int; 2023 Jan; 34(1):179-188. PubMed ID: 36287230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pooled analysis of three pharmacokinetic studies comparing biosimilar MB02 and reference bevacizumab.
    Miguel-Lillo B; Sánchez-Vidaurre S; Pérez Díaz L; Paravisini A
    Pharmacol Res Perspect; 2023 Dec; 11(6):e01139. PubMed ID: 37920875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I, randomized, double-blind, single-dose study to assess the pharmacokinetics, safety, and immunogenicity of the proposed biosimilar SCT630 and adalimumab in healthy Chinese subjects.
    Liu L; Qi L; Lei C; Wang Y; Zhang W; Liu Y; Li P; Bai H; Li Y; Li Y; Liu J; Xie L; Wang X
    Int Immunopharmacol; 2022 May; 106():108599. PubMed ID: 35193054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase I, Randomized, Double-Blind, Single-Dose, Parallel-Group Study to compare Pharmacokinetic Similarity, Safety, and Immunogenicity Between BAT2506 and Golimumab in Healthy Chinese Male Subjects.
    Wu M; Sun J; Wu D; Xu J; Wei J; Wang Z; Yu J; Li S; Zhang H; Ding Y
    Expert Opin Investig Drugs; 2021 Jan; 30(1):77-83. PubMed ID: 33241960
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.